E-Separation Solutions
Without question, the current acetonitrile shortage has become the hottest topic in the chromatography world in recent memory.
Without question, the current acetonitrile shortage has become the hottest topic in the chromatography world in recent memory. The influx of shortage-related articles, conservation tips, and even explorations of alternative separations instrumentation has been enormous at LCGC, with many brilliant and innovative ideas being presented to get laboratories through these hard times.
However, it is interesting that to date, so little attention has been paid to the underlying causes of this shortage, particularly in light of the large amounts of revenue that are tied to this seemingly innocuous solvent. Certainly, the reasons have been detailed, and the prevailing wisdom is that there are three: Hurricane Ike, the shutdown of one of the world’s largest acetonitrile producers in China, and, perhaps most tellingly, the decrease in production of acrylonitrile by car manufacturers, as acetonitrile is a byproduct of acrylonitrile production.
It is that third cause that is especially troubling, as it cuts to the heart of the current global economic crisis and at the same time, draws a direct link to the chromatography community. It is generally agreed that the subprime mortgage crisis was what started the global economic snowball rolling downhill, and this directly led to the depression of countless other markets, including the automobile industry and its industrial byproducts — such as acetonitrile. But all too often, it as at this point that “general agreement” ends, and the cries of “Wall Street greed” and “predatory lending” begin, as critical thought often gives way to populist anger.
For if we really want to get to the heart of why car production ground to a halt in the past year and hence, why you are currently doing all you can to preserve acetonitrile every day in the lab, one more logical step must be taken, and the populist anger aimed one rung higher on the ladder. While it is true that there have been many greedy individuals and corporations who contributed to the current economic mess, blaming them alone is a little like blaming a toddler for coloring the walls with markers you opened, handed him, and then asked him to use.
With “Government Sponsored Entities,” or GSEs, such as Freddie Mac and Fannie Mae at the heart of the mortgage crisis, one has only to connect the dots back to the late-1990s when their fatally flawed lending policies were enacted. At that time, GSEs were actively encouraged (some might say pushed by threat of investigation) by the presidential administration and its congressional allies to make the risky loans that resulted in the current mess — all in the name of expanding the dream of homeownership to borrowers who otherwise could not qualify. Stunningly, many of those same congressional leaders and high-ranking administration figures are the ones now leading the chorus against corporate greed and doing the most finger-pointing, which takes more than a little chutzpah. If we were to list names here, they would probably fill a phone book, but it is fairly safe to start at the top and work your down through our current congressional leadership.
So while the chromatography community waits — like the rest of the world — for the economy to recover and thereby allow the acetonitrile to begin flowing again, perhaps it would be helpful to affix the bullseye to the correct group of villains. It may not bring about the recovery any faster, but it might just help determine who in Washington still has a job come November 2010.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.